SCHEMBL241548

SCHEMBL241548

CC(=O)c1cc2ccccc2o1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.71
NPC1 O15118 9/20 0.62
RAB9A P51151 8/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
ALDH1A1 P00352 4/20 0.62
HPGD P15428 4/20 0.62
MAPK1 P28482 3/20 0.62
KDM4E B2RXH2 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
TSHR P16473 2/20 0.62
LMNA P02545 1/20 0.62
GLA P06280 1/20 0.62
GAA P10253 1/20 0.62
CASP1 P29466 1/20 0.62
BRCA1 P38398 1/20 0.62
CASP7 P55210 1/20 0.62
HSD17B10 Q99714 1/20 0.62
CA12 O43570 1/20 0.61
CYP1A2 P05177 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27690690 0.93 FLT3 (0.62) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
Benzofuran SCHEMBL2957261 0.88 FLT3 (0.57) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
Trifluoroacetic Acid SCHEMBL28751252 0.88 FLT3 (0.57) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL20280743 0.87 FLT3 (0.56) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6001320 0.85 ALDH1A1 (0.59) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6272805 0.85 FLT3 (0.67) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL8915455 0.83 FLT3 (0.64) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL244107 0.83 FLT3 (1.00) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL31061078 0.83 FLT3 (1.00) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3266442 0.83 FLT3 (0.51) FLT3NPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121584000-A Composite electrolyte, positive electrode plate and all-solid-state battery 绿能起源科技(江苏)有限公司 2026-02-27 CN claimed
CN-119753874-A Luminous anchor net material suitable for stress and preparation method thereof 中煤科工开采研究院有限公司 2025-04-04 CN claimed
CN-114957238-B 3-hydroxy-pyrrole-2-ketone compound containing 1,3, 4-thiadiazole and synthetic method and application thereof 南京工业大学 2024-02-06 CN claimed
CN-117486872-A Mechanical ball milling synthesis method of aminothiazole compound 浙江工业大学 2024-02-02 CN claimed
CN-117304135-A Synthesis method of 4-substituted-5H-1, 2, 3-dithiazole-5-thione and derivative 衡阳师范学院 2023-12-29 CN claimed
CN-114957238-A 3-hydroxy-pyrrole-2-ketone compound containing 1,3, 4-thiadiazole and synthetic method and application thereof 南京工业大学 2022-08-30 CN claimed
US-10920176-B2 Transparent liquids, in particular fabric treatment agents, comprising perfume and microcapsules with an odor modulator compound HENKEL AG & CO. KGAA (DE) 2021-02-16 US claimed
CN-110615771-A Method for directly synthesizing furazan oxide from methyl ketone 中国科学院青岛生物能源与过程研究所 2019-12-27 CN claimed
US-20190155975-A9 Antiperspirant and Deodorant Compositions Comprising Malodor Reduction Compositions THE PROCTER & GAMBLE COMPANY 2019-05-23 US claimed
US-20190010427-A1 SILICONE COMPOUNDS THE PROCTER & GAMBLE COMPANY 2019-01-10 US claimed
US-20050202505-A1 Method to identify modulators for human 3alpha-hydroxysteroid dehydrogenase FLOERSHEIM PHILIPP (CH) 2005-09-15 US claimed
EP-1421383-A2 METHOD TO IDENTIFY MODULATORS FOR HUMAN 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE Novartis AG (CH) 2004-05-26 EP claimed
WO-2003018830-A2 METHOD TO IDENTIFY MODULATORS FOR HUMAN 3α-HYDROXYSTEROID DEHYDROGENASE NOVARTIS AG (CH) 2003-03-06 WO claimed
EP-0703910-B1 BENZOYLBENZOFURANE DERIVATIVES FOR TREATMENT OF CARDIAC ARRHYTHMIA ARYX THERAPEUTICS (US) 1998-01-07 EP claimed
EP-0703910-A1 BENZOYLBENZOFURANE DERIVATIVES FOR TREATMENT OF CARDIAC ARRHYTHMIA Advanced Therapies, Inc. (US) 1996-04-03 EP claimed
US-5440054-A Compound for treatment of cardiac arrhythmia, synthesis, and methods of use ADVANCED THERAPIES, INC. (US) 1995-08-08 US claimed
WO-1994029289-A1 BENZOYLBENZOFURANE DERIVATIVES FOR TREATMENT OF CARDIAC ARRHYTHMIA ADVANCED THERAPIES, INC. (US) 1994-12-22 WO claimed
EP-0156331-B1 BENZOFURAN DERIVATIVES, PROCESSES FOR PREPARING THE SAME AND ANTIHYPERTENSIVE AGENTS CONTAINING THE SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 1989-05-31 EP claimed
US-4652566-A (2-HYDROXY-3-(4-PHENYLPIPERAZINYL)PROPOXY) BENZOFURAN DERIVATIVES; DECREASED SIDE EFFECTS KAKEN PHARMACEUTICAL CO., LTD. (JP) 1987-03-24 US claimed
EP-0156331-A2 Benzofuran derivatives, processes for preparing the same and antihypertensive agents containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 1985-10-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10920176-B2 Transparent liquids, in particular fabric treatment agents, comprising perfume and microcapsules with an odor modulator compound NEFM, TRPA1, ALOX5 FLT3 3319/4885NPC1 4292/4885RAB9A 4778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.